The complaint aims to stop the company from manufacturing and distributing animal drugs in conditions unsatisfactory to the minimum regulatory requirements to ensure safety and quality.
On Oct. 27, 2020, the United States filed a civil complaint against Med-Pharmex (MPX), a Pomona, CA-based animal health company, regarding its manufacturing and distribution of adulterated animal drugs.
According to a press release from the Department of Justice, the complaint aims to stop the company from manufacturing and distributing animal drugs in conditions unsatisfactory to the minimum regulatory requirements to ensure safety and quality. In the complaint, it is noted that FDA inspected the company site several times, which resulted in a warning letter in 2017 that noted deficiencies at the company including the failure to properly clean and disinfect areas used to manufacture sterile drugs and the failure to conform to current good manufacturing practices. Additionally, the complaint also mentions MPX’s failure to sufficiently examine reports of the death or illness of animals receiving MPX drugs, the press release said.
“Americans depend on animal drugs being safe and effective,” said Acting Assistant Attorney General Jeffrey Bossert Clark of the Justice Department’s Civil Division, in the press release. “We will continue working with FDA to ensure all drug manufacturers abide by public safety requirements.”
“Ensuring FDA-approved animal medications are safe, effective, and manufactured using current good manufacturing practices is an important part of the FDA’s mission to protect human and animal health,” added FDA Chief Counsel Stacy Amin, in the press release. “The FDA will continue to pursue actions against those who put animal patients in harm’s way by manufacturing and distributing adulterated animal drug products.”
Source: Department of Justice
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.